Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study

Overview of attention for article published in Frontiers in oncology, June 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (82nd percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 1 news outlet

twitter: 1 X user

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 7 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 1 news story.

HER2+ BC: Adding pertuzumab to trastuzumab+neoadjuvant chemotherapy confers benefits in the real world (of 11)

Pediatric News , 24 Jul 2023

Key clinical point: Findings from this real-world study supported the previous evidence for improved clinical outcomes on…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.